Paris, France, Cambridge (Massachusetts, United States), April 19, 2022 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company at the clinic specializing in the development of treatments that aim to slow the degenerative processes associated with aging and improve the functional results of patients suffering from age-related diseases, including respiratory failure in patients suffering from COVID-19, today announces that it will present and discuss the results of the Sarconeos (BIO101) development program in Sarcopenia at the 12th annual International Congress on Frailty and Sarcopenia (ICFSR) to be held online and also on-site in Boston from April 20 to 22, 2022.
The ICFSR is a major international scientific event on frailty and sarcopenia, bringing together the best researchers, doctors as well as pharmaceutical and biotechnology companies. On Friday, April 22, Cendrine Tourette, PhD (SARA Project Manager) and Jean Mariani, MD, PhD (Administrator) will make an oral presentation regarding the results of the SARA-INT Phase 2 trial for the treatment of Sarcopenia.